MiWEndo Solutions
MiWEndo Solutions is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at MiWEndo Solutions.
MiWEndo Solutions is a company.
Key people at MiWEndo Solutions.
Key people at MiWEndo Solutions.
MiWEndo Solutions is a medtech startup developing a low-cost microwave-based endoscopy accessory to automate polyp detection during colonoscopies, targeting early colorectal cancer (CRC) detection. The device attaches to standard colonoscopes, scans with a 360° field of view, alarms on polyp detection, and differentiates malignant from benign tissues without altering clinical workflows, addressing CRC—the second most common cancer in Europe with over 470,000 annual cases and 228,000 deaths.[1][5][6] It serves gastroenterologists and hospitals, solving limitations in current endoscopy like missed polyps (up to 25% miss rate implied by need for efficiency), overburdened screening programs, and high colonoscopy demand from aging populations.[1][2][6] At Technology Readiness Level (TRL) 7, it has shown high sensitivity/specificity in preclinical models (ex vivo, phantoms, porcine) and a pilot trial (MiWEndo I, N=15), with ongoing MiWEndo II (N=65); CE marking submission positions it for 2025 European launch.[1]
Growth momentum includes prototype validation, European patent protection (plus US/Japan filings), and clinical expansion, backed by EU funding that created five jobs and fostered institutional ties.[1][6]
MiWEndo Solutions was founded in 2019 as a spin-off from Universitat Pompeu Fabra (UPF), Universitat Politècnica de Catalunya (UPC), Hospital Clínic de Barcelona (HCB), and Institució Catalana de Recerca i Estudis Avançats (ICREA), promoted by UPF's BCN Medtech unit.[1][2][5] The idea emerged from collaboration between Marta Guardiola, an electrical engineer and CTO with microwave expertise, and Gloria Fernández-Esparrach, a HCB gastroenterologist specializing in endoscopy, who identified a medical need to overcome endoscopy's diagnostic limits.[1][2][4] Early traction came swiftly: a prototype demonstrated automatic polyp location in human tissue, validated in preclinical studies, leading to MiWEndo I pilot trial success; CEO Ignacio Belda joined to drive commercialization.[1][2][4] Pivotal moments include 2020 EU-funded prototype refinement and patent filings, with incorporation attended by institutional leaders like UPF's Jaume Badia and UPC's Francesc Torres.[2]
MiWEndo rides the AI/medtech wave in precision oncology, enhancing endoscopy amid rising CRC screening demands from aging populations and expanded programs, which strain endoscopy units with bottlenecks.[6] Timing aligns with post-2020 emphasis on non-invasive, efficient diagnostics—microwave imaging fills gaps in optical methods' ~20-25% miss rates for flat polyps, potentially curing >90% of cases via early intervention.[1][5] Market forces favor it: CRC's high incidence (top in Europe/US/Japan, 13M+ annual colonoscopies), EU funding for spin-offs, and patent protections enable global scaling.[2][6] It influences the ecosystem by strengthening academia-hospital ties (e.g., UPF-HCB-UPC), creating jobs, training students, and easing pathology burdens, paving for broader adoption of electromagnetic endoscopy adjuncts.[6]
MiWEndo is primed for 2025 CE approval and European launch, followed by US/Japan entry, accelerating via MiWEndo II data and partnerships.[1][2] Trends like AI-driven endoscopy, value-based care prioritizing efficiency, and CRC screening mandates will propel growth, potentially capturing share in a $5B+ global endoscopy market. Its influence may evolve from niche innovator to standard-of-care enabler, reducing mortality through ubiquitous polyp automation—transforming routine colonoscopies into proactive cancer killers, as pioneered by its engineer-physician origins.[1][5]
